VIKING THERAPEUTICS INC (VKTX)
US92686J1060 - Common Stock
Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...
1 Under-the-Radar Stock to Buy Before It Soars by 156%, According to Select Wall Street Analysts
This is a high-risk, high-reward stock.
Why Viking Therapeutics Stock Plummeted by 24% in December
Should You Buy the Dip on This High-Flying Stock?
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such...
3 Stocks That Could Be Monster Winners in 2025
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such...
Hot Obesity Drug Market Will Keep Investors Gripped Next Year
Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug developers vying for a piece of pharma’s hottest market.
Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?
My Top 10 Stocks to Buy for 2025
Why Viking Therapeutics Tumbled by More Than 10% This Week
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for.
Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review
Micron, Vertex, Novo Nordisk and Nike were notable losers on news.
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
Eli Lilly and Viking Therapeutics jumped on Novo's setback.
Noteworthy Wednesday Option Activity: NTGR, VKTX, ZS
What's Going On With Viking Therapeutics Stock On Wednesday?
On Wednesday, Merck & Co Inc (NYSE:MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture, and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche
Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments.
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
The weight-loss drugs space continues to heat up. Here's the latest news from the segment.
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030
Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Drugmakers often see phases of growth as they develop candidates for a high-potential treatment area or as they launch promising new products. Over time, you can benefit from these periods by buying shares of certain biotech and pharma companies and holding for the long term.
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street
It's been a good year for the stock market as a whole and a tremendous year for a couple of drugmaker start-ups. BTIG analyst Justin Zelin thinks Viking Therapeutics stock can reach $125 per share for a gain of about 166% over the next 12 months. If an experimental weight loss treatment it's developing continues to succeed in clinical trials, the stock could more than double again.
Viking Therapeutics is Now Oversold (VKTX)
Warning: This Skyrocketing Stock Has a Hidden Risk
This year the company reported solid results from trials of a candidate meant to address one of today's hottest growth areas: weight loss. The weight loss drug market may reach $130 billion by 2030, according to Goldman Sachs Research, an increase from its earlier estimate of $100 billion. Viking Therapeutics (NASDAQ: VKTX) saw its shares rise 121% in one trading session after its initial clinical trial report back in February.
Warning: This Skyrocketing Stock Has a Hidden Risk
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
The company is still suffering from the significant drop in sales of its coronavirus products and the less-than-impressive financial results it has produced during the past two years. Pfizer has, unquestionably, made progress. Many new approvals and acquisitions have expanded its lineup and pipeline.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such...
After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now?
After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now?
There's a growing number of companies entering the weight loss space, focusing on GLP-1 drugs which can be game changers for their businesses. At a cheaper valuation, has Viking Therapeutics become too good of a buy to pass up right now? Although it looks like there may be some mounting pessimism surrounding Viking Therapeutics stock recently, its shares are still up more than 180% this year, as of the end of last week.